BIRC2

Baculoviral IAP repeat-containing protein 2 · Q13490 · BIRC2 on Sugi Atlas →

41,205 patent compounds predicted against BIRC2, 20,658 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL728740	0.58	18/20
Hydrochloric Acid (SCHEMBL1272894)	0.71	15/20
Hydrochloric Acid (SCHEMBL894476)	0.57	15/20
Hydrochloric Acid (SCHEMBL894477)	0.57	15/20
SCHEMBL1164185	0.88	14/20
Hydrochloric Acid (SCHEMBL1273069)	0.87	14/20
SCHEMBL1273136	0.87	14/20
SCHEMBL1272461	0.78	14/20
SCHEMBL1272385	0.77	14/20
SCHEMBL1273005	0.77	14/20
SCHEMBL1272393	0.74	14/20
SCHEMBL1273012	0.74	14/20
SCHEMBL1272389	0.73	14/20
SCHEMBL1273008	0.73	14/20
SCHEMBL1272986	0.72	14/20
SCHEMBL1272987	0.72	14/20
Trifluoroacetic Acid (SCHEMBL1273079)	0.71	14/20
SCHEMBL1272963	0.70	14/20
Trifluoroacetic Acid (SCHEMBL1272294)	0.70	14/20
SCHEMBL1272929	0.70	14/20

Clinical trials — most relevant to BIRC2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)	PHASE1/PHASE2	WITHDRAWN
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma	PHASE2	ACTIVE_NOT_RECRUITING
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer	PHASE2	COMPLETED
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer	PHASE2	COMPLETED
9-ING-41 in Patients With Advanced Cancers	PHASE2	ACTIVE_NOT_RECRUITING
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	PHASE2	NOT_YET_RECRUITING
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma	PHASE1	ACTIVE_NOT_RECRUITING
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	PHASE1	COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma	PHASE1	COMPLETED
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma	PHASE1	ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma	PHASE1	COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
Molecular Mechanism of Nasopharyngeal Carcinoma	nan	UNKNOWN
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer	nan	RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction	nan	UNKNOWN
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a BIRC2 binder may also engage these)

Protein	Name	Similarity
Q62210	—	1.000	Q62210 →
Q9R0I6	—	1.000	Q9R0I6 →
BIRC3	Baculoviral IAP repeat-containing protein 3	0.998	landscape →
Q5BKL8	—	0.998	Q5BKL8 →
A5D8Q0	—	0.997	A5D8Q0 →
Q90660	—	0.995	Q90660 →
O08863	—	0.995	O08863 →
A1E2V0	—	0.994	A1E2V0 →
XIAP	E3 ubiquitin-protein ligase XIAP	0.994	landscape →
Q95M72	—	0.993	Q95M72 →
Q95M71	—	0.990	Q95M71 →
O62640	—	0.987	O62640 →
P25799	—	0.987	P25799 →
BIRC8	Baculoviral IAP repeat-containing protein 8	0.987	landscape →
Q60989	—	0.987	Q60989 →
Q9DDT2	—	0.987	Q9DDT2 →
Q9H0M0	—	0.987	Q9H0M0 →
Q9FT70	—	0.986	Q9FT70 →
Q7SIG6	—	0.985	Q7SIG6 →
Q95LP3	—	0.985	Q95LP3 →
Q8AXC7	—	0.985	Q8AXC7 →
Q8TDB6	—	0.985	Q8TDB6 →
KDM5D	Lysine-specific demethylase 5D	0.984	landscape →
Q4R4A2	—	0.984	Q4R4A2 →
F4I2Y3	—	0.984	F4I2Y3 →
Q9FY74	—	0.984	Q9FY74 →
Q6IVY4	—	0.984	Q6IVY4 →
Q76II0	—	0.984	Q76II0 →
Q9LSP8	—	0.984	Q9LSP8 →
Q9R016	—	0.984	Q9R016 →